pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Loqtorzi
drug · antibody
save

toripalimab

Phase 2updated 3mo ago
by $CHRS Coherus Oncology, Inc.🔗 ChEMBL
Phase 2
community read0 votes

🐶 often sniffed alongside

top 3
  • tagBreast Cancer3 co-mentions · 1 sources
  • tagOncology2 co-mentions · 1 sources
  • companyShanghai Longfine Biotechnology Co Ltd1 co-mentions · 1 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 52 investigational indications.

indications

indications
Melanoma

targets

Programmed cell death protein 1

all catalysts(1)

phase 2 completion · 1
Apr 30, 2026
phase 2 completion
4mo ago
Shanghai Longfine Biotechnology Co Ltd — toripalimab (Phase II Trial Completion)
toripalimab
→

Trials studying toripalimab

  • EP1An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumorsrecruitingn=60
  • phase4A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancerrecruitingn=100
  • phase2Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancerrecruitingn=60
  • EP1An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumorsnot yet recruitingn=50
  • phase3LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinomarecruitingn=400
  • phase2A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung CancerInhibitors or Platinum-Based Agents for Small Cell Lung Cancer.not yet recruitingn=200
  • phase1A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancernot yet recruitingn=33
  • phase2Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)recruitingn=75
more trials →

News(0)

no news has mentioned this drug yet

brand
Loqtorzi
trade names
Loqtorzi
generic
toripalimab-tpzi
MOA
Programmed cell death protein 1 antagonist
indication
Esophageal Squamous Cell Carcinoma (ESCC)
phase
phase_2
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 5m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?